Abstract
Introduction: Because prolactin excess and hyperthyroidism are often complicated by hyperglycemia and impaired insulin sensitivity, many patients with both these disorders are treated with metformin. This drug inhibits secretory function of overactive anterior pituitary cells, including lactotrophs. The purpose of the current study was to investigate whether metformin action on prolactin oversecretion is impacted by coexisting hyperthyroidism. Methods: Our prospective, cohort study included two groups of women in reproductive age requiring metformin therapy with mild or moderate hyperprolactinemia. Patients with concomitant grade 1 subclinical hyperthyroidism (group A) and individuals without thyroid pathology (group B) were matched for age, insulin sensitivity, and total prolactin levels. Glucose homeostasis markers, thyroid-stimulating hormone (TSH), free thyroid hormones, total and monomeric prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, adrenocorticotropic hormone, IGF-1, and peripheral markers of thyroid hormone action (ferritin and osteocalcin) were measured before and after 6-month metformin therapy. Results: At baseline, both groups differed in levels of TSH, free thyroid hormones, ferritin, and osteocalcin. Although metformin reduced glucose, improved insulin sensitivity and reduced total and monomeric prolactin in both groups, these effects were more pronounced in group A than group B. The impact on prolactin in group A correlated with concentrations of free thyroid hormones. Only in group A, did metformin slightly increase FSH and LH concentrations. In women with hyperthyroidism and without thyroid pathology, there were no statistical differences between baseline and follow-up levels of the remaining variables. Conclusion: The study results suggest that hyperthyroidism potentiates the impact of metformin on secretory function of overactive lactotrophs in reproductive-age women.
Journal Section:
Research Article
References
1.
Bo
QJ
, Wang
ZM
, Li
XB
, Ma
X
, Wang
CY
, de Leon
J
. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: a systematic review
. Psychiatry Res
. 2016
;237
:257
–63
. 2.
Krysiak
R
, Kowalcze
K
, Szkrobka
W
, Okopien
B
. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia
. Eur J Intern Med
. 2016
;30
:94
–8
. 3.
Zheng
W
, Yang
XH
, Cai
DB
, Ungvari
GS
, Ng
CH
, Wang
N
, et al. Adjunctive metformin for antipsychotic-related hyperprolactinemia: a meta-analysis of randomized controlled trials
. J Psychopharmacol
. 2017
;31
(5
):625
–31
. 4.
Zhu
C
, Li
R
, Ju
M
, Xiao
X
, Yuan
TF
, Jin
Z
, et al. Metformin in the treatment of amisulpride-induced hyperprolactinemia: a clinical trial
. Front Mol Neurosci
. 2022
;15
:892477
. 5.
Krysiak
R
, Okrzesik
J
, Okopien
B
. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study
. Endocrine
. 2015
;49
(1
):242
–9
. 6.
Banaszewska
B
, Pawelczyk
L
, Spaczynski
RZ
, Duleba
AJ
. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment
. J Clin Endocrinol Metab
. 2011
;96
(11
):3493
–501
. 7.
Krysiak
R
, Szkróbka
W
, Okopień
B
. Alternative treatment strategies in women poorly tolerating moderate doses of bromocriptine
. Exp Clin Endocrinol Diabetes
. 2017
;125
(6
):360
–4
. 8.
Portari
LH
, Correa-Silva
SR
, Abucham
J
. Prolactin response to metformin in cabergoline-resistant prolactinomas: a pilot study
. Neuroendocrinology
. 2022
;112
(1
):68
–73
. 9.
Krysiak
R
, Szkróbka
W
, Okopień
B
. A neutral effect of metformin treatment on macroprolactin content in women with macroprolactinemia
. Exp Clin Endocrinol Diabetes
. 2017
;125
(4
):223
–8
. 10.
Lupoli
R
, Di Minno
A
, Tortora
A
, Ambrosino
P
, Lupoli
GA
, Di Minno
MN
. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies
. J Clin Endocrinol Metab
. 2014
;99
(1
):E143
–8
. 11.
Amirabadizadeh
A
, Amouzegar
A
, Mehran
L
, Azizi
F
. The effect of metformin therapy on serum thyrotropin and free thyroxine concentrations in patients with type 2 diabetes: a meta-analysis
. Sci Rep
. 2023
;13
(1
):18757
. 12.
Krysiak
R
, Szkróbka
W
, Okopień
B
. The effect of metformin on serum gonadotropin levels in postmenopausal women with diabetes and prediabetes: a pilot study
. Exp Clin Endocrinol Diabetes
. 2018
;126
(10
):645
–50
. 13.
Guan
Y
, Wang
D
, Bu
H
, Zhao
T
, Wang
H
. The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials
. Int J Endocrinol
. 2020
;2020
:5150684
. 14.
Krysiak
R
, Szkróbka
W
, Okopień
B
. Sex-dependent effect of metformin on serum prolactin levels in hyperprolactinemic patients with type 2 diabetes: a pilot study
. Exp Clin Endocrinol Diabetes
. 2018
;126
(6
):342
–8
. 15.
Krysiak
R
, Szkróbka
W
, Okopień
B
. The Impact of ethinyl estradiol on metformin action on prolactin levels in women with hyperprolactinemia
. Exp Clin Endocrinol Diabetes
. 2021
;129
(1
):22
–8
. 16.
Krysiak
R
, Kowalcze
K
, Okopień
B
. The impact of metformin on prolactin levels in postmenopausal women
. J Clin Pharm Ther
. 2021
;46
(5
):1433
–40
. 17.
Krysiak
R
, Kowalcze
K
, Szkróbka
W
, Okopień
B
. Impaired prolactin-lowering effects of metformin in women with polycystic ovary syndrome
. J Clin Med
. 2023
;12
(17
):5474
. 18.
Krysiak
R
, Kowalcze
K
, Madej
A
, Okopień
B
. The effect of metformin on plasma prolactin levels in young women with autoimmune thyroiditis
. J Clin Med
. 2023
;12
(11
):3769
. 19.
Vigersky
RA
, Filmore-Nassar
A
, Glass
AR
. Thyrotropin suppression by metformin
. Metab
. 2006
;91
(1
):225
–7
. 20.
Krysiak
R
, Szkrobka
W
, Okopien
B
. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism
. Exp Clin Endocrinol Diabetes
. 2015
;123
(4
):205
–8
. 21.
Kinoshita
S
, Hosomi
K
, Yokoyama
S
, Takada
M
. Inverse association between metformin and amiodarone-associated extracardiac adverse events
. Int J Med Sci
. 2020
;17
(3
):302
–9
. 22.
Han
YE
, Hwang
S
, Kim
JH
, Byun
JW
, Yoon
JS
, Lee
EJ
. Biguanides metformin and phenformin generate therapeutic effects via AMP-activated protein kinase/extracellular-regulated kinase pathways in an in vitro model of Graves’ orbitopathy
. Thyroid
. 2018
;28
(4
):528
–36
. 23.
Song
E
, Koo
MJ
, Noh
E
, Hwang
SY
, Park
MJ
, Kim
JA
, et al. Risk of diabetes in patients with long-standing Graves’ disease: a longitudinal study
. Endocrinol Metab
. 2021
;36
(6
):1277
–86
. 24.
Auriemma
RS
, De Alcubierre
D
, Pirchio
R
, Pivonello
R
, Colao
A
. The effects of hyperprolactinemia and its control on metabolic diseases
. Expert Rev Endocrinol Metab
. 2018
;13
(2
):99
–106
. 25.
Galling
B
, Roldán
A
, Nielsen
RE
, Nielsen
J
, Gerhard
T
, Carbon
M
, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis
. JAMA Psychiatry
. 2016
;73
(3
):247
–59
. 26.
Lee
SY
, Pearce
EN
. Hyperthyroidism: a review
. JAMA
. 2023
;330
(15
):1472
–83
. 27.
Ross
DS
, Burch
HB
, Cooper
DS
, Greenlee
MC
, Laurberg
P
, Maia
AL
, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis
. Thyroid
. 2016
;26
(10
):1343
–421
. 28.
Krysiak
R
, Kowalcze
K
, Okopień
B
. Subclinical hyperthyroidism enhances gonadotropin-lowering effects of metformin in postmenopausal women
. J Clin Pharmacol
. 2025
;65
:318
–27
. 29.
American Diabetes Association Professional Practice Committee
. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024
. Diabetes Care
. 2024
;47
(Suppl 1
):S20
–42
. 30.
Biondi
B
, Bartalena
L
, Cooper
DS
, Hegedüs
L
, Laurberg
P
, Kahaly
GJ
. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism
. Eur Thyroid J
. 2015
;4
(3
):149
–63
. 31.
Matthews
DR
, Hosker
JP
, Rudenski
AS
, Naylor
BA
, Treacher
DF
, Turner
RC
. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
. Diabetologia
. 1985
;28
(7
):412
–9
. 32.
Romijn
JA
. Hyperprolactinemia and prolactinoma
. Handb Clin Neurol
. 2014
;124
:185
–95
. 33.
Wróbel
MP
, Marek
B
, Kajdaniuk
D
, Rokicka
D
, Szymborska-Kajanek
A
, Strojek
K
. Metformin - a new old drug
. Endokrynol Pol
. 2017
;68
(4
):482
–96
. 34.
Dutta
S
, Shah
RB
, Singhal
S
, Dutta
SB
, Bansal
S
, Sinha
S
, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes
. Drug Des Devel Ther
. 2023
;17
:1907
–32
. 35.
Krysiak
R
, Kowalcze
K
, Okopień
B
. Impact of metformin on hypothalamic-pituitary-thyroid axis activity in women with autoimmune and non-autoimmune subclinical hypothyroidism: a pilot study
. Pharmacol Rep
. 2024
;76
(1
):195
–206
. 36.
Dietrich
JW
, Müller
P
, Schiedat
F
, Schlömicher
M
, Strauch
J
, Chatzitomaris
A
, et al. Nonthyroidal illness syndrome in cardiac illness involves elevated concentrations of 3,5-diiodothyronine and correlates with atrial remodeling
. Eur Thyroid J
. 2015
;4
(2
):129
–37
. 37.
Krysiak
R
, Okopien
B
. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone
. Clin Endocrinol
. 2011
;75
(3
):404
–6
. 38.
Refetoff
S
. Resistance to thyroid hormone
. Clin Lab Med
. 1993
;13
(3
):563
–81
. 39.
Herzig
S
, Shaw
RJ
. AMPK: guardian of metabolism and mitochondrial homeostasis
. Nat Rev Mol Cell Biol
. 2018
;19
(2
):121
–35
. 40.
Foretz
M
, Guigas
B
, Bertrand
L
, Pollak
M
, Viollet
B
. Metformin: from mechanisms of action to therapies
. Cell Metab
. 2014
;20
(6
):953
–66
. 41.
Tosca
L
, Froment
P
, Rame
C
, McNeilly
JR
, McNeilly
AS
, Maillard
V
, et al. Metformin decreases GnRH- and activin-induced gonadotropin secretion in rat pituitary cells: potential involvement of adenosine 5’ monophosphate-activated protein kinase (PRKA)
. Biol Reprod
. 2011
;84
(2
):351
–62
. 42.
Takano
AP
, Diniz
GP
, Barreto-Chaves
ML
. AMPK signaling pathway is rapidly activated by T3 and regulates the cardiomyocyte growth
. Mol Cell Endocrinol
. 2013
;376
(1–2
):43
–50
. 43.
Hermann
R
, Mestre Cordero
VE
, Fernández Pazos
MDLM
, Córdoba
MF
, Reznik
FJ
, Vélez
DE
, et al. Role of AMPK in the protective effects exerted by triiodothyronine in ischemic-reperfused myocardium
. J Mol Endocrinol
. 2021
;66
(3
):207
–21
. 44.
Ortega-González
C
, Cardoza
L
, Coutiño
B
, Hidalgo
R
, Arteaga-Troncoso
G
, Parra
A
. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome
. J Endocrinol
. 2005
;184
:234
–9
.45.
Nedvídková
J
, Pacák
K
, Haluzík
M
, Nedvídek
J
. The regulation of adenohypophyseal prolactin secretion: effect of triiodothyronine and methylene blue on estrogenized rat adenohypophysis
. Physiol Res
. 2000
;49
(Suppl 1
):S27
–35
.46.
Olson
AL
. Regulation of GLUT4 and insulin-dependent glucose flux
. ISRN Mol Biol
. 2012
;2012
:856987
. 47.
Tavares
G
, Marques
D
, Barra
C
, Rosendo-Silva
D
, Costa
A
, Rodrigues
T
, et al. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes
. Mol Metab
. 2021
;51
:101241
. 48.
Herman
R
, Kravos
NA
, Jensterle
M
, Janež
A
, Dolžan
V
. Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport
. Int J Mol Sci
. 2022
;23
(3
):1264
. 49.
Jia
X
, Zhai
T
, Zhang
JA
. Metformin reduces autoimmune antibody levels in patients with Hashimoto’s thyroiditis: a systematic review and meta-analysis
. Autoimmunity
. 2020
;53
(6
):353
–61
. 50.
Euser
AM
, Zoccali
C
, Jager
KJ
, Dekker
FW
. Cohort studies: prospective versus retrospective
. Nephron Clin Pract
. 2009
;113
(3
):c214
–7
. 51.
Streiner
DL
. Regression toward the mean: its etiology, diagnosis, and treatment
. Can J Psychiatry
. 2001
;46
(1
):72
–6
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
